NAMS Menopause Certification Exam (MSCP) 2026 150 Practice Questions with Evidence Based Rationales grade A+

NAMS Menopause Certification Exam (MSCP)
2026 150 Practice Questions with Evidence-
Based Rationales grade A+

EXAM OVERVIEW

Category Details

Certification Menopause Society Certified Practitioner (MSCP) — formerly NCMP

Administering The Menopause Society (formerly NAMS)
Body

Content Domains Physiology/Pathophysiology (19%), Symptoms (20%), Health Disorders (21%), Treatment (16%),
Preventive Care (24%)

Question Format Multiple-choice, case-based scenarios

Reference STRAW+10 staging system, 2025/2026 Candidate Handbook



SECTION 1: PHYSIOLOGY & PATHOPHYSIOLOGY OF THE MENOPAUSE TRANSITION

Domain 1 — ~19% of Exam



1. What is the "climacteric phase"?

 A) The final menstrual period

 B) The period of endocrinologic transitory psyc, somatic, and hologic changes around the time
of menopause

 C) The perimenopause only

 D) The postmenopausal period

Rationale: The climacteric phase encompasses the transition from the reproductive stage to the non-
reproductive stage. It is the period of endocrinologic, somatic, and transitory psychologic changes that
occur around menopause .



2. What is the definition of "early menopause"?

 A) LMP before age 40

,  B) LMP before age 45

 C) LMP before age 50

 D) LMP after age 55

Rationale: Early menopause is defined as the last menstrual period (LMP) occurring before age 45. This is
distinguished from primary ovarian insufficiency (POI), which occurs before age 40 .



3. What is the definition of "late menopause"?

 A) LMP after age 50

 B) LMP after age 54

 C) LMP after age 55

 D) LMP after age 60

Rationale: Late menopause is defined as an LMP after age 54. The average age of natural menopause in
North American women is approximately 51 years .



4. What term describes menopause that occurs before age 40?

 A) Early menopause

 B) Primary ovarian insufficiency (POI)

 C) Late menopause

 D) Premenopause

Rationale: Primary ovarian insufficiency (POI) is defined as the loss of ovarian function before the age of
40. This is distinguished from early menopause, which occurs between ages 40 and 45 .



5. According to the STRAW+10 staging system, what characterizes the "early menopause transition"
(stage –2)?

 A) 60 or more consecutive days of amenorrhea

 B) Persistent difference of 7 days or more in the length of consecutive cycles

 C) Heavy menstrual bleeding

 D) Regular cycles 26–35 days

Rationale: Stage –2 (early menopause transition) is marked by persistent difference of ≥ 7 days in the
length of consecutive cycles and is when cycle irregularity begins .

,6. According to the STRAW+10 staging system, what characterizes the "late menopause transition"
(stage –1)?

 A) 60 or more consecutive days of amenorrhea

 B) Persistent difference of 7 days or more in cycle length

 C) Regular cycles 26–35 days

 D) Onset of vasomotor symptoms only

Rationale: Stage –1 (late menopause transition) is defined by ≥ 60 consecutive days of amenorrhea in
women aged ≥ 40 years. This indicates progression toward the final menstrual period .



7. In which post-menopausal stage do vasomotor symptoms (VMS) predominate?

 A) Stage +1a, +1b, +1c (early postmenopause)

 B) Stage +2 (late postmenopause)

 C) Menopause transition

 D) Late reproductive years

Rationale: In early postmenopause (stage +1a, +1b, +1c) — which is the first 2-3 years after the final
menstrual period (FMP) — FSH rises, estradiol decreases, and VMS predominate. Later stages are
dominated by urogenital and somatic aging .



8. What are the typical endocrine laboratory findings after menopause?

 A) Low FSH, low LH, high estradiol

 B) Elevated FSH and LH, low estradiol

 C) Low FSH, high LH, high progesterone

 D) Normal FSH, low estradiol

Rationale: After menopause, the ovaries no longer produce significant estrogen, leading to loss of
negative feedback on the pituitary and elevated FSH and LH. Low estradiol is the expected finding .



9. Which laboratory marker is considered a superior marker of ovarian reserve and prediction of time
to menopause?

 A) FSH

 B) LH

,  C) AMH (anti-Müllerian hormone)

 D) Inhibin B

Rationale: AMH is produced by the ovarian follicle pool and declines as follicles are depleted, making it a
better reflection of ovarian reserve and the best single predictor of time to menopause. FSH can be
variable in perimenopause .



10. What does the luteal out-of-phase (LOOP) event explain?

 A) Elevated FSH in early menopause

 B) Elevated estrogen levels in perimenopausal women

 C) Low progesterone in perimenopause

 D) Androgen excess in menopause

Rationale: The LOOP event explains why some perimenopausal women have elevated estrogen levels. In
the early menopause transition, elevated FSH recruits a second follicle during the luteal phase, causing a
follicular-phase-like rise in estradiol superimposed on the mid-to-late luteal phase of the ovulatory cycle .



11. Where are estrogen receptors located? (Select all that apply)

 A) Vagina

 B) Vulva

 C) Urethra

 D) Trigone of the bladder

Rationale: Estrogen receptors are abundant throughout the lower urinary and genital tracts, including
the vagina, vulva, urethra, and trigone of the bladder. This explains why estrogen therapy is effective for
genitourinary syndrome of menopause (GSM) .



12. What are the vaginal changes associated with menopause?

 A) Thickening of the vaginal epithelium

 B) Thinning, loss of elasticity, and loss or absence of rugae

 C) Increased rugae and increased elasticity

 D) No change

Rationale: Menopause leads to thinning of the vaginal epithelium, loss of elasticity, and loss or absence
of rugae due to estrogen deficiency. These changes contribute to GSM symptoms such as dyspareunia,
dryness, and irritation .